Strensiq[™] support with MAP is only a phone call away

- MAP is a no-charge program that provides education, assistance with access to Strensiq, and ongoing treatment support for people living with hypophosphatasia, their families, and their healthcare providers
- MAP is staffed with experienced Nurse Case Managers and Reimbursement Specialists who have in-depth knowledge of hypophosphatasia and expertise in healthcare reimbursement
- The MAP team is available Monday to Friday (9 am to 7 pm) to help answer questions and offer one-on-one support



Contact MAP to obtain time-saving assistance with education, access to Strensiq, and treatment support. 1-844-MAP-PAM2 (1-844-627-7262)

Monday – Friday

9 am – 7 pm EST

Strensiq (asfotase alfa), indicated as enzyme replacement therapy for patients with confirmed diagnosis of paediatric-onset hypophosphatasia, has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. For further details, please refer to the Strensiq Product Monograph.


Strensiq is a trademark and Alexion is a registered trademark of Alexion Pharmaceuticals, Inc. Copyright © 2015, Alexion Pharmaceuticals, Inc. All rights reserved. CA/STQ-HPP/15/0005E











MAP offers education, assistance gaining access to Strensiq[™], and ongoing treatment support for people living with hypophosphatasia, and the healthcare professionals who take care of them.



One-on-one, confidential support throughout the treatment journey

MAP provides education, assistance gaining access to StrensiqTM, and treatment support for people living with hypophosphatasia, their caregivers, and their healthcare providers. The MAP team is staffed with experienced Nurse Case Managers and Reimbursement Specialists who have in-depth knowledge of hypophosphatasia and expertise in healthcare reimbursement. Upon enrolment, patients have access to the team of experts who will be their primary contact throughout their treatment journey.

MAP offers a personalized approach to treatment support



Physician and patient support

- · Coordination of Strensiq shipment and delivery
- · Coordination of in-home and clinic injection training
- Nurse telephone support, including injection support
- · Patient education on disease and treatment
- Prescription renewals



Reimbursement assistance

- Navigation of all avenues of reimbursement to ensure maximum coverage for Strensiq
- Coordination of co-pay support
- Facilitation of all follow-ups with payers to minimize any challenges with reimbursement
- Monitoring of coverage renewals to avoid any interruption in treatment
- In-office reimbursement support by a nurse or reimbursement expert for physicians





Nursing services

- · Coordination and assistance with in-home or clinic injection training
- Experienced nurses across the country trained in providing specialty services to patients, their caregivers, and healthcare providers



Pharmacy services

- Direct-to-home and clinic delivery of Strensig
- Pharmacy and distribution coordination available across the country
- Expertise in the unique requirements of specialty medications
- The MAP pharmacy is seamlessly integrated with the distribution centre

The Metabolic Assistance Program (MAP): Helping you every step of the way

MAP offers education, assistance gaining access to Strensiq[™], and ongoing treatment support for patients with hypophosphatasia and the healthcare professionals who take care of them.



Contact MAP to obtain time-saving assistance 1-844-MAP-PAM2 (1-844-627-7262) Monday – Friday 9 am – 7 pm EST





Strensiq (asfotase alfa), indicated as enzyme replacement therapy for patients with confirmed diagnosis of paediatric-onset hypophosphatasia, has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. For further details, please refer to the Strensiq Product Monograph.